Qi Xingshun, Wang Jigang, Yu Xiaonan, De Stefano Valerio, Li Hongyu, Wu Chunyan, Zeng Qingwei, Zhang Yongguo, Ren Linan, Lin Hao, Deng Jiao, Guo Xiaozhong
Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang 110840, China.
Department of Hematology, General Hospital of Shenyang Military Area, Shenyang 110840, China.
Transl Gastroenterol Hepatol. 2017 Sep 12;2:71. doi: 10.21037/tgh.2017.08.08. eCollection 2017.
Hemocoagulase has been successfully used for the management of bleeding in patients undergoing surgery. Local spray of hemocoagulase during endoscopic therapy may be effective for the management of gastrointestinal bleeding. In China, intravenous infusion of hemocoagulase is given by some physicians for the treatment of gastrointestinal bleeding. However, the potential adverse events secondary to hemocoagulase, such as hypofibrinogenemia, are poorly recognized. In this paper, we reported an elderly patient with type II respiratory failure in whom hemocoagulase might induce hypofibrinogenemia and further worsen gastrointestinal bleeding. We highlighted that fibrinogen levels should be cautiously monitored in patients receiving hemocoagulase.
血凝酶已成功用于接受手术患者的出血管理。在内镜治疗期间局部喷洒血凝酶可能对胃肠道出血的管理有效。在中国，一些医生会静脉输注血凝酶来治疗胃肠道出血。然而，血凝酶继发的潜在不良事件，如低纤维蛋白原血症，却鲜为人知。在本文中，我们报告了一名患有II型呼吸衰竭的老年患者，血凝酶可能诱发其低纤维蛋白原血症并进一步加重胃肠道出血。我们强调，接受血凝酶治疗的患者应谨慎监测纤维蛋白原水平。
